Blurbs

Assembly Biosciences (ASMB) Gets a Hold Rating from H.C. Wainwright

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Assembly Biosciences (ASMBResearch Report), with a price target of $2.50. The company’s shares closed last Tuesday at $2.22.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.8% and a 36.8% success rate. Arce covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Paratek Pharmaceuticals, and Galmed Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Assembly Biosciences with a $9.17 average price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $3.94 and a one-year low of $1.32. Currently, Assembly Biosciences has an average volume of 510.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.

Read More on ASMB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos